Bufei Jianpi Granule for Delaying Pulmonary Function Decline in Early-Stage COPD

• Status: Not yet recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to establish the treatment scheme of Bufei Jianpi granule for early-stage (GOLD stage 1 or 2) chronic obstructive pulmonary disease (COPD), delaying pulmonary function decline and forming high quality evidence.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Henan University of Traditional Chinese Medicine
• Collaborator: Jiangsu Province Hospital of Traditional Chinese Medicine

Criteria

Inclusion Criteria:

• A confirmed diagnosis of early-stage (GOLD stage 1 or 2) COPD.

• Syndrome differentiation meets criteria of Qi deficiency of the lung syndrome, Qi deficiency of the lung and spleen syndrome or Qi deficiency of the lung and kidney syndrome.

• Age ranges from 40 years to 80 years.

• With informed consent signed.

Exclusion Criteria:

• Pregnant and lactating women.

• Patients with severe cardiovascular and cerebrovascular diseases.

• Patients with severe liver and kidney diseases.

• Patients with asthma, bronchiectasis, active pulmonary tuberculosis, pulmonary embolism or other severe respiratory diseases.

• Patients with tumor after resection, radiotherapy or chemotherapy in the past 5 years.

• Patients with severe neuromuscular disorders, severe arthritis or severe peripheral vascular diseases.

• Patients with severe cognitive and psychiatric disorders.

• Patients with diabetes.

• People who are allergic to the treatment drugs.

• Patients who have participated in other clinical studies in the past 4 weeks.

• Patients who have experienced one or more acute exacerbation in the past 4 weeks.